CN111836634A - 使用可溶性成纤维细胞生长因子受体3(sfgfr3)多肽治疗异常内脏脂肪沉积 - Google Patents

使用可溶性成纤维细胞生长因子受体3(sfgfr3)多肽治疗异常内脏脂肪沉积 Download PDF

Info

Publication number
CN111836634A
CN111836634A CN201880061038.6A CN201880061038A CN111836634A CN 111836634 A CN111836634 A CN 111836634A CN 201880061038 A CN201880061038 A CN 201880061038A CN 111836634 A CN111836634 A CN 111836634A
Authority
CN
China
Prior art keywords
composition
polypeptide
sfgfr3
fgfr3
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880061038.6A
Other languages
English (en)
Chinese (zh)
Inventor
埃尔维雷·古兹
斯特凡妮·加西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blue Coast University
French Institute Of Health And Medicine
Centre National de la Recherche Scientifique
Pfizer Inc
Original Assignee
Blue Coast University
French Institute Of Health And Medicine
Centre National de la Recherche Scientifique
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blue Coast University, French Institute Of Health And Medicine, Centre National de la Recherche Scientifique, Pfizer Inc filed Critical Blue Coast University
Publication of CN111836634A publication Critical patent/CN111836634A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880061038.6A 2017-09-20 2018-09-20 使用可溶性成纤维细胞生长因子受体3(sfgfr3)多肽治疗异常内脏脂肪沉积 Pending CN111836634A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561140P 2017-09-20 2017-09-20
US62/561,140 2017-09-20
PCT/EP2018/075471 WO2019057820A1 (en) 2017-09-20 2018-09-20 ABNORMAL VISCERAL GREASE DEPOSITION TREATMENT USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES

Publications (1)

Publication Number Publication Date
CN111836634A true CN111836634A (zh) 2020-10-27

Family

ID=63878625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880061038.6A Pending CN111836634A (zh) 2017-09-20 2018-09-20 使用可溶性成纤维细胞生长因子受体3(sfgfr3)多肽治疗异常内脏脂肪沉积

Country Status (12)

Country Link
US (1) US20200297799A1 (enExample)
EP (1) EP3684394A1 (enExample)
JP (1) JP7335247B2 (enExample)
KR (1) KR20200103621A (enExample)
CN (1) CN111836634A (enExample)
AU (1) AU2018335837A1 (enExample)
BR (1) BR112020005459A2 (enExample)
CA (1) CA3076396A1 (enExample)
IL (1) IL273203A (enExample)
MX (1) MX2020003114A (enExample)
PH (1) PH12020550461A1 (enExample)
WO (1) WO2019057820A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110272900A (zh) * 2019-04-19 2019-09-24 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
NL2020176B1 (en) * 2017-12-22 2019-07-02 Van Der Hoeven Horticultural Projects B V Greenhouse
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
WO2024147597A1 (ko) * 2023-01-03 2024-07-11 서울대학교산학협력단 Fgfr3 발현 또는 활성 억제제의 퇴행성 신경질환 치료 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109850A1 (en) * 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
CN105121464A (zh) * 2013-01-16 2015-12-02 法国健康和医学研究院 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽
WO2016110786A1 (en) * 2015-01-07 2016-07-14 Therachon Solube fgfr3 decoys for treating skeletal growth disorders
CN106662577A (zh) * 2014-01-24 2017-05-10 恩格姆生物制药公司 结合蛋白及其使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102432192B1 (ko) * 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109850A1 (en) * 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
CN105121464A (zh) * 2013-01-16 2015-12-02 法国健康和医学研究院 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽
US20150344855A1 (en) * 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
CN106662577A (zh) * 2014-01-24 2017-05-10 恩格姆生物制药公司 结合蛋白及其使用方法
WO2016110786A1 (en) * 2015-01-07 2016-07-14 Therachon Solube fgfr3 decoys for treating skeletal growth disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUO等: "Protein tolerance to random amino acid change" *
NPCHELLAIAH等: "Mappingligand binding domains in chimeric fibroblast growth factorreceptor molecules. Multiple regions determine ligand binding specificity" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110272900A (zh) * 2019-04-19 2019-09-24 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用

Also Published As

Publication number Publication date
EP3684394A1 (en) 2020-07-29
WO2019057820A1 (en) 2019-03-28
AU2018335837A1 (en) 2020-04-23
BR112020005459A2 (pt) 2020-09-29
JP2020534367A (ja) 2020-11-26
IL273203A (en) 2020-04-30
US20200297799A1 (en) 2020-09-24
RU2020113712A3 (enExample) 2022-01-14
JP7335247B2 (ja) 2023-08-29
MX2020003114A (es) 2020-10-20
KR20200103621A (ko) 2020-09-02
CA3076396A1 (en) 2019-03-28
PH12020550461A1 (en) 2021-03-22
RU2020113712A (ru) 2021-10-20

Similar Documents

Publication Publication Date Title
JP7335247B2 (ja) 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置
US11697678B2 (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
US11814654B2 (en) Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
WO2016110786A1 (en) Solube fgfr3 decoys for treating skeletal growth disorders
JP2020015733A (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
RU2794170C2 (ru) ЛЕЧЕНИЕ АНОМАЛЬНОГО ОТЛОЖЕНИЯ ВИСЦЕРАЛЬНОГО ЖИРА С ИСПОЛЬЗОВАНИЕМ РАСТВОРИМЫХ ПОЛИПЕПТИДОВ РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 3 (sFGFR3)
HK40039240A (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
NZ790135A (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
HK1217959B (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039240

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201027